Scotland rapped over cardiovascular technology access failures
This article was originally published in Clinica
Much has been achieved in Scotland to improve access to optimum cardiovascular (CV) care, but more needs to be done to ensure more appropriate use of key medical technologies and medicines, according to a review of Scotland’s Heart Disease Improvement Programme (HDIP).
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.